tiprankstipranks
Trending News
More News >
Sartorius AG (DE:SRT3)
:SRT3

Sartorius (SRT3) AI Stock Analysis

Compare
36 Followers

Top Page

DE

Sartorius

(LSE:SRT3)

Rating:60Neutral
Price Target:
€225.00
▲(0.49%Upside)
Sartorius's overall stock score reflects a strong financial performance supported by robust cash flow and asset management. However, high leverage and declining profitability are areas of concern. The technical analysis indicates a bearish trend, and the high P/E ratio suggests the stock is overvalued. These factors lead to a cautious outlook for the stock.
Positive Factors
Earnings
Sartorius AG delivered a 7% beat on EBITDA compared to consensus, which is considered a positive result.
Growth Expectations
The guidance for EBITDA was raised to 30% at the high point, indicating strong performance expectations.
Investment Potential
The price target has an upside potential of 46.8%, suggesting a strong growth opportunity for investors.
Negative Factors
Bioprocessing Trends
Bioprocessing recovery still below trend, implying that this is largely consumables driven.
Financial Performance
EBITDA was down 12%, in line with consensus, reflecting the volume and product mix effects.
Product Segment Performance
Lab products and services showed weakness with a decline in revenue and missed EBITDA estimates, highlighting concerns in equipment purchasing.

Sartorius (SRT3) vs. iShares MSCI Germany ETF (EWG)

Sartorius Business Overview & Revenue Model

Company DescriptionSartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
How the Company Makes MoneySartorius generates revenue primarily through the sale of its bioprocess solutions and laboratory products. The Bioprocess Solutions segment accounts for the majority of its revenue, providing integrated solutions that streamline the development and manufacture of biopharmaceuticals. This includes the sale of proprietary technologies and consumables, such as filtration and purification systems, cell culture media, and single-use systems, which are critical for the production of biologics. The Lab Products & Services segment complements this by offering laboratory instruments, consumables, and services for research and quality assurance. Sartorius also leverages strategic partnerships and collaborations with biopharmaceutical companies to enhance its product offerings and expand its market reach, contributing to its financial performance.

Sartorius Financial Statement Overview

Summary
Sartorius demonstrates stable cash flow and asset management, with strong cash generation capabilities. However, profitability has been pressured in recent periods, with declining margins and revenue growth. Increasing leverage could pose future risks if not managed carefully. The company exhibits a balanced overall financial position, though attention to profitability and debt levels is necessary.
Income Statement
72
Positive
Sartorius shows a stable gross profit margin of around 45% to 50% over the periods, indicating efficient cost management. The net profit margin in the TTM stands at 3.63%, a drop from previous years, primarily due to decreased EBIT and net income. Revenue growth has been inconsistent, with a decline in 2025 TTM compared to the previous year. The EBIT and EBITDA margins have also contracted, pointing to reduced operational efficiency.
Balance Sheet
67
Positive
The company's debt-to-equity ratio increased slightly, reflecting higher leverage, which may pose financial risks. However, the equity ratio remains stable, suggesting a balanced capital structure. Return on equity has decreased to 4.62% in the TTM, indicating lower profitability for shareholders. While the company maintains solid asset management, rising liabilities could be a concern.
Cash Flow
78
Positive
Sartorius's operating cash flow has improved in the TTM, suggesting strong cash-generating ability. Free cash flow growth is robust, rising by approximately 21% compared to the previous period, indicating good cash management. The operating cash flow to net income ratio is elevated, reflecting strong cash conversion despite lower net income. Overall, cash flow management appears solid, supporting financial stability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.44B3.38B3.40B4.17B3.45B2.34B
Gross Profit1.56B1.52B1.57B2.20B1.84B1.21B
EBITDA831.60M786.80M873.10M1.54B945.12M662.13M
Net Income125.10M84.00M205.20M913.10M426.98M321.47M
Balance Sheet
Total Assets2.94B10.10B9.76B6.98B5.70B4.70B
Cash, Cash Equivalents and Short-Term Investments158.80M828.70M394.20M196.80M360.99M217.65M
Total Debt1.08B4.56B5.31B2.54B2.08B2.09B
Total Liabilities1.79B6.21B7.00B4.32B3.98B3.30B
Stockholders Equity856.70M2.76B2.07B1.99B1.26B1.05B
Cash Flow
Free Cash Flow687.30M566.30M293.90M211.60M458.65M271.27M
Operating Cash Flow1.04B976.20M853.60M734.20M865.81M511.52M
Investing Cash Flow-374.40M-425.80M-2.82B-1.13B-569.61M-1.27B
Financing Cash Flow-944.30M-128.30M2.17B209.90M-165.18M907.47M

Sartorius Technical Analysis

Technical Analysis Sentiment
Positive
Last Price223.90
Price Trends
50DMA
219.85
Positive
100DMA
222.59
Positive
200DMA
228.41
Negative
Market Momentum
MACD
1.06
Negative
RSI
59.64
Neutral
STOCH
72.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT3, the sentiment is Positive. The current price of 223.9 is above the 20-day moving average (MA) of 212.29, above the 50-day MA of 219.85, and below the 200-day MA of 228.41, indicating a neutral trend. The MACD of 1.06 indicates Negative momentum. The RSI at 59.64 is Neutral, neither overbought nor oversold. The STOCH value of 72.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:SRT3.

Sartorius Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
DESHL
76
Outperform
$52.35B25.1511.14%2.02%5.83%13.44%
DEFME
68
Neutral
€14.32B23.164.37%2.96%0.10%27.83%
DEAFX
62
Neutral
€5.05B31.877.48%1.05%5.21%-39.36%
DEFRE
61
Neutral
€23.77B56.916.28%2.02%-18.90%
60
Neutral
€13.74B158.243.55%0.34%3.99%-36.36%
DEMRK
59
Neutral
€48.87B17.349.74%1.96%2.38%3.49%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:SRT3
Sartorius
223.90
3.74
1.70%
DE:FME
Fresenius Medical Care AG & Co. KGaA
48.32
13.69
39.52%
DE:AFX
Carl Zeiss Meditec
56.60
-7.81
-12.12%
DE:FRE
Fresenius SE & Co. KGaA
42.28
14.48
52.09%
DE:MRK
Merck KGaA
112.70
-35.80
-24.11%
DE:SHL
Siemens Healthineers AG
47.42
-4.91
-9.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 21, 2025